ESMO Congress | Conference

Dr Allaf on Perioperative Nivolumab Vs Observation Following Nephrectomy in RCC

September 10th 2022

Mohamad Ezzeddine Allaf, MD, discusses the results of perioperative nivolumab vs observation in patients with renal cell carcinoma who undergo nephrectomy.

Trastuzumab Deruxtecan Maintains Clinical Benefit in Metastatic Gastric/GEJ Cancer

September 10th 2022

Trastuzumab deruxtecan continued to demonstrate a clinical benefit and tolerable safety profile for patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a trastuzumab-based regimen.

Amcenestrant Provides Numerically Similar PFS to Endocrine Therapy in Endocrine-Resistant ER+ Advanced Breast Cancer

September 10th 2022

Amcenestrant did not significantly improve progression-free survival over physician’s choice of endocrine monotherapy in patients with endocrine-resistant, estrogen receptor–positive, HER2-negative advanced breast cancer, but it did provide a benefit that was numerically comparable, according to data from the phase 2 AMEERA-3 trial.

Second-line Cemiplimab Produces Long-Term OS Benefit in Recurrent/Metastatic Cervical Cancer

September 10th 2022

Cemiplimab maintained an overall survival benefit vs chemotherapy as a second-line treatment for patients with recurrent or metastatic cervical cancer who received prior platinum-based chemotherapy.

Sacituzumab Govitecan-hziy Demonstrates Promising Efficacy in HER2-low/HER2-0 Metastatic Breast Cancer

September 10th 2022

Sacituzumab govitecan improved progression-free survival and overall response rate among patients with HER2-low or HER2 immunohistochemistry zero, hormone receptor–positive metastatic breast cancer.

ADP-A2M4CD8 Shows Promising Activity Across MAGE-A4+ Unresectable or Metastatic Tumor Types

September 10th 2022

An updated analysis of the phase 1 SURPASS trial showed that ADP-A2M4CD8, a next-generational autologous T-cell receptor designed to patients with solid tumors, may be an effective therapy in MAGE-A4-positive disease.

Lasofoxifene Improves Responses Vs Fulvestrant in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer

September 10th 2022

Single-agent lasofoxifene did not produce a statistically significant improvement in progression-free survival vs fulvestrant for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

Neoadjuvant T-VEC Plus Surgery Demonstrates Long-Term Efficacy in Resectable Melanoma

September 10th 2022

Neoadjuvant talimogene laherparepvec plus surgery provided sustained, durable improvements in efficacy vs surgery alone in patients with resectable stage IIIB to IVM1a melanoma.

Abemaciclib Plus Trastuzumab Results in Numerical OS Improvement Vs SOC in HR+, HER2+ Advanced Breast Cancer

September 10th 2022

The addition of abemaciclib to trastuzumab, with or without fulvestrant, provided a numerical overall survival improvement over standard-of-care trastuzumab plus chemotherapy in patients with hormone receptor–positive, HER2-positive advanced breast cancer, according to data from the monarcHER trial.

Exposure to Environmental Carcinogens May Increase Risk for EGFR+ NSCLC

September 10th 2022

Increased exposure to particulate matter may be a mechanistic driver for EGFR-positive non–small cell lung cancer, prompting a focus on limiting exposure to air pollutants and an increased need for molecular testing.

LEAP-002 Trial Misses Primary End Points, But Data Support Role of Lenvatinib Monotherapy as SOC in Frontline HCC

September 10th 2022

Although the primary end points of the phase 3 LEAP-002 trial did not meet prespecified statistical significance with regard to survival benefit achieved with lenvatinib plus pembrolizumab, the median overall survival observed with lenvatinib monotherapy supports its role as a standard of care in frontline advanced hepatocellular carcinoma treatment.

TILs Demonstrate Improved PFS Vs Ipilimumab in Unresectable Melanoma

September 10th 2022

A tumor-infiltrating lymphocyte therapy manufactured at various centers in the Netherlands Cancer Institute elicited a 50% reduction in the risk of progression or death vs ipilimumab in patients with stage IIIC/IV unresectable, treatment-refractory melanoma.

Camrelizumab/Rivoceranib Combo Significantly Improves Survival Over Sorafenib in Unresectable HCC

September 10th 2022

First-line treatment with camrelizumab plus rivoceranib resulted in a significant improvement in progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma.

Nirogacestat Improves PFS in Progressing Desmoid Tumors

September 10th 2022

Nirogacestat led to a 71% reduction in the risk of disease progression or death compared with placebo in patients with progressive desmoid tumors.

First-line Dalpiciclib Significantly Improves PFS Outcomes for Patients With HR+/HER2– Advanced Breast Cancer

September 9th 2022

The combination of the CDK4/6 inhibitor dalpiciclib plus letrozole or anastrozole reduced the risk of disease progression by 49% vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.

CLDN6 CAR T-Cell Therapy Shows Encouraging Efficacy in Relapsed/Refractory Advanced Solid Tumors

September 9th 2022

The investigational carcinoembryonic antigen claudin 6 (CLDN6)–directed CAR T-cell therapy BNT211-01 displayed clinical activity both as monotherapy and in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.

Oleclumab/Durvalumab Plus Chemotherapy Combo Fails to Reach Clinical Benefit End Point in Advanced TNBC

September 9th 2022

Adding oleclumab to durvalumab and chemotherapy did not increase the clinical benefit rate vs durvalumab plus chemotherapy alone as a first-line treatment for patients with advanced triple-negative breast cancer.

Sacituzumab Govitecan Produces Significant Efficacy Benefits in Pretreated HR+/HER2- Metastatic Breast Cancer

September 9th 2022

Sacituzumab govitecan generated statistically significant and clinically meaningful benefits in overall survival and responses vs physician’s choice of treatment in pretreated patients with hormone receptor–positive, HER2-negative metastatic breast cancer who were resistant to endocrine therapy.

Abemaciclib Plus Aromatase Inhibitor Generates Survival Benefit in HR+/HER2- Breast Cancer

September 9th 2022

The addition of abemaciclib to a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer.

Preoperative Nivolumab Alone or With Relatlimab Allows for Surgical Feasibility in Resectable NSCLC

September 9th 2022

Preoperative nivolumab with or without relatlimab increased surgical feasibility in patients with resectable non–small cell lung cancer.